Navigation Links
Ganeden Biotech and Pathway International Announce Exclusive Distribution Partnership
Date:2/3/2010

CLEVELAND, Feb. 3 /PRNewswire/ -- Ganeden Biotech Inc., maker of the patented probiotic strain GanedenBC30®, today announced a partnership with Pathway International Pty Ltd. to exclusively distribute GanedenBC30 in all Australian and New Zealand markets.

The partnership will provide growth opportunities for Ganeden Biotech through increased distribution channels and access to an exclusive international supply chain network of leading manufacturers in Australia and New Zealand.

"Partnering with Pathway International is an important step in achieving our global expansion goals for 2010," said Andrew Lefkowitz, Ganeden Biotech president and CEO. "We are confident that Pathway International's proven track record in successfully distributing innovative health and wellness ingredients will help our probiotic reach consumers in these markets looking to improve their digestive health and boost immunity with probiotic-enhanced food, beverage and supplement products."

Since 2008, GanedenBC30 has been incorporated in more than 40 products widely distributed throughout North America. Due to the unique ability of the shelf-stable probiotic to survive harsh manufacturing processes, it can be incorporated into a variety of products ranging from frozen yogurt to baked goods.

"We look forward to a long-term relationship with Ganeden Biotech through which we can help introduce GanedenBC30 to new markets and manufacturers interested in innovative functional ingredients," said Wayne Coote, managing director of Pathway International.

About Ganeden Biotech

Founded in 1996, Ganeden Biotech Inc. is based in Cleveland, Ohio, and is the largest seller of over-the-counter probiotics in the U.S. through its Digestive Advantage® and Sustenex™ brands. It also licenses its patented probiotic bacteria, GanedenBC30, for use in commercial food and beverage applications, medical foods, nutraceuticals and in animal health industries. GanedenBC30 is self-affirmed GRAS (Generally Recognized As Safe) by an independent panel assembled to assess its safety in use as a food ingredient. For more information about licensing opportunities visit ganedenlabs.com and for probiotic supplement information visit digestiveadvantage.com or sustenex.com.

About Pathway International Pty Ltd.

Pathway is the exclusive distributor in Australia and New Zealand for leading suppliers of high quality and innovative ingredients that add value to the health care and nutrition industries.  For more information visit www.pathway.net.au.

SOURCE Ganeden Biotech Inc.

RELATED LINKS
http://www.ganedenlabs.com
http://www.pathway.net.au

'/>"/>

SOURCE Ganeden Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Ganeden Biotech, Racconto Introduce First Probiotic Pasta Line
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Biotech Finishes on a High in August, Burrill Report Says
4. Oncolytics Biotech Inc. reports positive interim results of UK phase Ia/Ib trials
5. Spectrum Pharmaceuticals to Present at the Biotechnology Industry Organization Investor Forum
6. Biotech delists shares from TSXV, continues OTCBB trading
7. Frutarom Gewurzmuller and Blessing Biotech Acquisition Conference Call Scheduled for Monday, October 15, 2007
8. MichBio Announces Formation of Biotechnology Legislative Caucus
9. Oncolytics Biotech Inc. announces approval for UK clinical trial
10. Not just humans benefit from animal biotechnology
11. Biotech adds Central American markets to Sucanon distribution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Houston, TX (PRWEB) , ... February 24, 2017 ... ... now offering promotions on tooth replacement options at his office, Antoine Dental Center. ... dental implants for $18,499. Some restrictions may apply, but patients can learn more ...
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis of genetic variants implicated ... to eight genes that may explain why susceptibility to one of the disorders could ... study published today in the journal npj Schizophrenia. , “There is a wealth ...
(Date:2/24/2017)... New York, NY (PRWEB) , ... February 24, 2017 , ... ... urges: “Security needs to be a top priority because it’s not if you will ... in online safety, especially when it comes to digital health care. , Improvements in ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: ... ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, as ... attempts to overcome them. , Schanssema, initially unsure of the career path he wanted ...
(Date:2/24/2017)... ... February 24, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... concerning this present generation. Yisrayl makes an astounding statement when he says that ... explains that the Bible details the current times so plainly that anyone should be ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 2017  This report analyzes the worldwide markets for ... Products: Intermediates, Analytical, and Others. The End ... and Agrochemicals. The report provides separate comprehensive analytics for ... Europe , and Rest of World. Annual estimates ... 2022. Also, a six-year historic analysis is provided for ...
(Date:2/24/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Urinary Incontinence Drugs Price Analysis and ... global Urinary Incontinence market. The research answers the following questions: ... for Urinary Incontinence and their clinical attributes? How are they positioned ...
(Date:2/23/2017)... MINNEAPOLIS , Feb. 23, 2017  Cogentix Medical, ... manufactures and markets innovative proprietary products for the urology ... and fiscal year ended December 31, 2016 before the ... The Company will host a conference call and ... on Thursday, March 9, 2017 at 11:00 a.m. Eastern ...
Breaking Medicine Technology: